Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
about
Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?Benefits and adverse effects of endocrine therapy17α-ethynyl-5α-androstane-3α, 17β-diol treatment of MNU-induced mammary cancer in ratsEstrogen receptor testing and 10-year mortality from breast cancer: A model for determining testing strategyWorry about cancer progression and low perceived social support: implications for quality of life among early-stage breast cancer patients.Therapeutic impacts of microRNAs in breast cancer by their roles in regulating processes involved in this disease.
P2860
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
@en
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
@nl
type
label
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
@en
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
@nl
prefLabel
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
@en
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer
@en
P2093
P2860
P304
P356
10.3747/CO.V16I0.457
P478
16 Suppl 2
P577
2009-07-01T00:00:00Z